- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The weak companies could be clobbered.
Regulators say company squelched competing drug for infant seizures.
Drugmaker faced antitrust charges over 2013 Synacthen purchase.
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.